- Home
- MRVL vs AZN Comparison
MRVL vs AZN Comparison
Compare MRVL & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVL | AZN |
|---|---|---|
| Founded | 1995 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.9B | 316.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | MRVL | AZN |
|---|---|---|
| Price | $275.13 | $183.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 32 | 1 |
| Target Price | ★ $120.28 | N/A |
| AVG Volume (30 Days) | ★ 59.8M | 1.9M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | 0.15% | ★ 1.73% |
| EPS Growth | ★ 400.98 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $8,194,600,000.00 | N/A |
| Revenue This Year | $35.14 | $10.34 |
| Revenue Next Year | N/A | $6.43 |
| P/E Ratio | $6,975.75 | ★ $31.91 |
| Revenue Growth | ★ 42.09 | N/A |
| 52 Week Low | $61.44 | $68.62 |
| 52 Week High | $329.88 | $212.71 |
Technical Indicators
Market Signals| Indicator | MRVL | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 52.86 |
| Support Level | $78.57 | $180.98 |
| Resistance Level | $324.20 | $191.50 |
| Average True Range (ATR) | 27.91 | 2.98 |
| MACD | -3.75 | 0.42 |
| Stochastic Oscillator | 32.36 | 80.83 |
Price Performance
Historical ComparisonAbout MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.